sb 203580 has been researched along with xylazine in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (xylazine) | Trials (xylazine) | Recent Studies (post-2010) (xylazine) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 1,981 | 207 | 526 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hossain, M; Liu, L; Xu, N | 1 |
1 other study(ies) available for sb 203580 and xylazine
| Article | Year |
|---|---|
Pharmacological inhibition of p38 mitogen-activated protein kinases affects KC/CXCL1-induced intraluminal crawling, transendothelial migration, and chemotaxis of neutrophils in vivo.
Topics: Animals; Cells, Cultured; Chemokine CXCL1; Chemotaxis, Leukocyte; Enzyme Inhibitors; Imidazoles; Ketamine; Male; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; Neutrophils; p38 Mitogen-Activated Protein Kinases; Pyridines; Transendothelial and Transepithelial Migration; Xylazine | 2013 |